KCT0009050已完成Unknown
A Prospective, Multi-national, Multicenter, Randomized Controlled Trial to Evaluate Safety and Effectiveness of Endoscopic Hemostatic Powder, ‘Nexpowder’ for Hemostatic Treatments of Nonvariceal, Upper Gastrointestinal Bleeding
extbiomedical0 个研究点目标入组 352 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 352
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1.Males or females of Age of 19 (Nineteen) or Older
- •(In case of Age of 75 (Seventy-Five) or older or if patient falls under emergencycondition, a written consent from the patient's guardian or legal representativeis required)
- •2.Indication of non-variceal upper gastrointestinal bleeding.
- •3.Forrest scores Ia, Ib or IIa by endoscopy findings
- •(Patients with class IIb or adherent clot, were reevaluated for class Ia, Ib or IIa after intensive irrigation procedure was performed to remove the clot)
- •4.Subjects who voluntarily agreed to the clinical trial and who were willing toand could comply with the study protocol
排除标准
- •1.Patients, who are unable to receive endoscopic treatment due to comorbidity
- •2.The 30-day follow-up is not possible.
- •3.Patients who are going through Pregnancy or breastfeeding
- •4.Endoscopic treatment is prohibited because of comorbidity
- •5.Patients who participated in the related clinical trials that can affect the studyresults within the past month
- •6.Other cases in which participation in the study is not appropriate by thejudgment of the investigators
研究者
相似试验
尚未招募
3 期
A clinical trial to study the effects of two drugs, HemoRel®-A Lyophilized for Intravenous Solution and Immunate� Lyophilized for Intravenous Solution in patients with Hemophilia A (Congenital Clotting Factor VIII Deficiency) or Acquired Coagulation Factor VIII DeficiencyCTRI/2013/07/003796Pharmasyntez JSC Russia16
已完成
2 期
Irbesartan & Amlodipine combination in controlling blood pressure.CTRI/2009/091/000580SanofiSynthelabo India Limited240
进行中（未招募）
1 期
Belimumab in Remission of VasculitisWegener’s granulomatosis (WG)Microscopic polyangiitis (MPA)VasculitisMedDRA version: 18.0Level: LLTClassification code 10047888Term: Wegener's granulomatosisSystem Organ Class: 10047065 - Vascular disordersMedDRA version: 18.0Level: PTClassification code 10063344Term: Microscopic polyangiitisSystem Organ Class: 10047065 - Vascular disordersEUCTR2011-004569-33-DEHuman Genome Sciences Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)100
进行中（未招募）
1 期
Belimumab in Remission of VasculitisEUCTR2011-004569-33-BEHuman Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)100
进行中（未招募）
1 期
Belimumab in Remission of VasculitisWegener’s granulomatosis (WG)Microscopic polyangiitis (MPA)VasculitisMedDRA version: 18.0Level: LLTClassification code 10047888Term: Wegener's granulomatosisSystem Organ Class: 10047065 - Vascular disordersMedDRA version: 18.0Level: PTClassification code 10063344Term: Microscopic polyangiitisSystem Organ Class: 10047065 - Vascular disordersEUCTR2011-004569-33-PLHuman Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)100